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Abstract
Live-attenuated SIV vaccines (LAVs) have been the most effective to date in preventing or partially controlling infection by
wild-type SIV in non-human primate models of HIV-1 transmission to women acting by mechanisms of protection that are
not well understood. To gain insights into mechanisms of protection by LAVs that could aid development of effective
vaccines to prevent HIV-1 transmission to women, we used in situ tetramer staining to determine whether increased
densities or changes in the local distribution of SIV-specific CD8 T cells correlated with the maturation of SIVDnef vaccine-
induced protection prior to and after intra-vaginal challenge with wild-type SIVmac251. We evaluated the immunodominant
Mamu-A1*001:01/Gag (CM9) and Mamu-A1*001:01/Tat (SL8) epitope response in genital and lymphoid tissues, and found
that tetramer+ cells were present at all time points examined. In the cervical vaginal tissues, most tetramer+ cells were
distributed diffusely throughout the lamina propria or co-localized with other CD8 T cells within lymphoid aggregates. The
distribution and densities of the tetramer+ cells at the portal of entry did not correlate with the maturation of protection or
change after challenge. Given these findings, we discuss the possibility that changes in other aspects of the immune system,
including the quality of the resident population of virus-specific effector CD8 T cells could contribute to maturation of
protection, as well as the potential for vaccine strategies that further increase the size and quality of this effector population
to prevent HIV-1 transmission.
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Introduction
While there have been heartening advances in antiretroviral
therapies that have converted HIV-1 infection in the developed
world to a chronic but manageable disease, it is clear that better
measures for prevention are needed to contain the continuing
growth of a pandemic that has already claimed more than 25
million lives and currently afflicts 34 million people [1]. This is
especially the case for women because of the increasing
feminization of the pandemic epicenter in sub-Saharan Africa
where 75 percent of the HIV-1 infected population ages 15–24 are
females [1,2]. Development of a prophylactic vaccine to prevent
HIV infection represents the most effective, economical, and
universal solution to achieving this goal, but thus far in human
trials, vaccine candidates have been at best marginally effective
[3,4]. The SIV-infected rhesus macaque model of HIV is a
powerful system being used to gain insights into HIV/SIV
pathogenesis and aid in the development of an effective HIV
vaccine. Some promising vaccine strategies tested in rhesus
macaques include vaccines that mediate sustained presentation
of SIV viral epitopes, such as live-attenuated SIVs (LAV) [5] and
vaccines based on persistent recombinant herpes virus vectors,
including recombinant cytomegalovirus (CMV) vaccines [6,7] and
recombinant rhadinovirus vaccines [8]. Arguably the most
effective vaccine evaluated to date in this system is the LAV
SIVDnef which suppressed viral replication in 95% of macaques
challenged with wild-type (WT)-SIV, with 50% of challenged
animals showing apparent sterilizing immunity[5,9–15], and
delayed the acquisition of WT-SIV infection after repeated low
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dose challenge [16]. Recent macaque studies using other vaccine
approaches have shown promise, including vaccination with
recombinant yellow fever virus and recombinant adenovirus
vectors expressing immunodominant CD8 T cell epitopes, which
demonstrated that virus-specific CD8 T cells can control WT-SIV
infection [17]. Many other strategies including using viral DNA,
viral particles and/or recombinant non-persisting viral vectors that
express viral epitopes have also shown promise in suppressing viral
replication and/or preventing infection from WT-SIV (a few of
which we cite here) [18–21].
While there has been much recent progress in employing
nonhuman primate models to aid development of an effective HIV
vaccine, using a variety of different vaccine approaches, the
efficacy of the LAV SIVDnef remains a benchmark for the field,
despite the fact that the underlying mechanism(s) of vaccine
protection remain to be elucidated. Thus, the robust protection
afforded by intravenous (iv) SIVDnef vaccination against WT-SIV
challenge by iv, rectal and vaginal routes [5,9–16], supports studies
of SIVDnef vaccination to identify correlates of protection that
could provide insight and principles to guide further development
of an effective HIV-1 vaccine. To that end, we investigated and
report here an analysis of the densities and locations after SIVDnef
vaccination of virus-specific CD8 T cells that recognize immuno-
dominant epitopes in Gag and Tat in the genital and lymphoid
tissues of rhesus macaques.
The hypothesis underlying these studies was that SIVDnef
vaccination might protect in part by converting the ‘‘too little and
too late’’ CD8 T cell response to these immunodominant epitopes
in unvaccinated animals [22,23] to an ‘‘enough and soon enough’’
response in the vaccinated animals, sufficient to contain infection
at the portal of entry or the lymphoid tissues (LTs) to which
infection subsequently spreads. This hypothesis was founded in
previous studies in the SIV-rhesus macaque vaginal challenge
model [22,23], which models HIV-1 transmission to women,
where the CD8 T cell response was described as ‘‘too little and too
late’’ for the following reasons. First, the peak of the immunodo-
minant response occurred after the peak of virus replication in the
lymphoid tissues (LT) that are the principal sites of virus
production, persistence and pathology, such as the massive
depletion of CD4 T cells in the gut, and thus too late to prevent
this loss. Second, the magnitude of the CD8 T cell response was
also insufficient to achieve the high effector to target cell ratios
(E:T) in vivo in systemic LTs that correlate with 100-fold
reductions in tissue viral load (VL) compared to peak VLs [24],
and thus too little in that sense to control infection. However, in
the cervical vaginal tissues, the higher E:T ratios were associated
with reductions from peak of this magnitude [24] and thus the
response is mainly too late. This latter finding suggested that a
resident or rapid responder population of virus-specific CD8 T
cells at the portal of entry and throughout the LTs to which
infection spreads could be ‘‘enough and soon enough’’ to contain
infection locally or after dissemination.
We therefore undertook studies of the location and dynamics of
the immunodominant CD8 T cell response to vaccination with
SIVmac239-Dnef and the response in vaccinated animals to high
dose vaginal challenge with wild type SIVmac251 (hereafter, WT-
SIV) to see if vaccination might induce and maintain a resident or
rapid responder population of CD8 T cells that would be enough
and soon enough to contain infection at the portal of entry or after
dissemination to LTs. We focused on a comparison of samples
obtained 5 and 20 weeks after SIVDnef vaccination and after
vaginal challenge at 20 weeks with WT-SIV. A comparison of 5
and 20 weeks after SIVDnef vaccination is pertinent to this study
because protection provided by live-attenuated SIVDnef vaccina-
tion takes 15–20 weeks to ‘‘mature.’’ Animals challenged with
WT-SIV before 15 weeks post-SIVDnef vaccination show little to
no suppression of viral replication, but when challenged after 15
weeks post-vaccination, 95% of the animals suppress viral
replication with 50% showing apparent sterilizing immunity
[12,25]. This maturation process suggests involvement of adaptive
immune components, including fully developed memory respons-
es, in protection, and thus a CD8 T cell correlate of protection
might be identified by comparing SIV-specific CD8 T cells in
cervical vaginal tissues and LTs at 5 weeks post-SIVDnef
vaccination when the animals are not protected, with 20 weeks
post-vaccination when there is sterilizing protection in half the
animals and significant reductions in VLs in the remainder
compared to unvaccinated controls.
Materials and Methods
Ethics statement
The 16 female Mamu-A1*001:01 (formerly Mamu A*01 [26])
Indian-derived rhesus macaque monkeys (Macacca mulatta)
described in this study were housed at the New England Primate
Center (NEPRC) in accordance with the regulations of the
American Association of Accreditation of Laboratory Animal Care
and the standards of the Association for Assessment and
Accreditation of Laboratory Animal Care International. All
protocols and procedures were approved by the relevant
Institutional Animal Care and Use Committee which was the
Harvard Medical Area (HMA) Standing Committee on Animals at
Harvard Medical School. All animals were housed indoors in an
SOP-driven, AAALAC-accredited facility. Husbandry and care
met the guidance of the Animal Welfare Regulations, OLAW
reporting and the standards set forth in The Guide for the Care
and Use of Laboratory Animals. All research animals were
enrolled in the NEPRC behavioral management program,
including an IACUC-approved plan for Environmental Enrich-
ment for research primates. This program included regular
behavioral assessments, and provision of species appropriate
manipulanda, and foraging opportunities. This protocol had an
IACUC-approved exemption from social housing based on
scientific justification. Primary enclosures consisted of stainless
steel primate caging provided by a commercial vendor. Animal
body weights and cage dimensions were regularly monitored.
Overall dimensions of primary enclosures (floor area and height)
met the specifications of The Guide for the Care and Use of
Laboratory Animals, and the Animal Welfare Regulations
(AWR’s). Further, all primary enclosures were sanitized every 14
days at a minimum, in compliance with AWRs. Secondary
enclosures (room level) met specifications of The Guide with
respect to temperature, humidity, lighting and noise level. The
animals were provided ad lib access to municipal source water,
offered commercial monkey chow twice daily, and offered fresh
produce a minimum of three times weekly. Light cycle was
controlled at 12/12 hours daily. The animals were subject to twice
daily documented observations by trained animal care and
veterinary staff, and enrolled in the facility’s environmental
enrichment, and preventative health care programs. Euthanasia
took place at defined experimental endpoints using protocols
consistent with the American Veterinary Medical Association
(AVMA) guidelines. Animals were first sedated with intramuscular
ketamine hydrochloride at 20 mg/kg body followed by sodium
pentobarbital ($100 mg/kg) intravenously to achieve euthanasia.
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Vaccination and Vaginal challenge
Animals were negative for antibodies to HIV type 2, SIV type D
retrovirus, and simian T-cell lymphotropic virus type 1. Animals
were vaccinated by infecting intravenously with 25 ng of a stock of
SIVmac239Dnef supplied by Dr. Ronald Desrosiers (NEPRC),
and, when indicated, challenged vaginally twice on the same day
(separated by 4 hours) with 105 TCID50 of SIVmac251 supplied
by Dr. Christopher Miller (CNPRC).
Tissue collection and processing
At the time of euthanasia, genital tissues including, vagina
(vestibule, middle, and near cervix), cervix (endo and ecto), uterus,
and lymphoid tissues including, genital, mesenteric, axillary, and
inguinal lymph nodes, spleen, and ileum were collected from each
animal. Freshly dissected tissues were placed in tubes containing
chilled RPMI media with heparin (100ug/ml or 18.7 U/ml)
added as an RNase inhibitor and were shipped overnight on ice
from the New England Primate Research Center to the University
of Minnesota.
In situ tetramer staining combined with
immunohistochemistry
Animals with Mamu-A1*001:01 MHC class 1 alleles were
selected for this study because, in this model system, immunodo-
minant CD8 T cell responses to Gag and Tat epitopes represent
approximately 70% of the total CD8 T cell response [27], and we
have MHC tetramer reagents and methods available to stain the
immunodominant SIV-specific CD8 T cells in situ. In situ
tetramer staining combined with immunohistochemistry was
performed similarly as previously described [28,29]. Biotinylated
Mamu-A1*001:01 molecules loaded with Gag181–189 CTPY-
DINQM (CM9) peptides were purchased from Beckman Coulter
Immunomics. Mamu-A1*001:01 molecules loaded with Tat
STPESANL (SL8) peptides or an irrelevant negative control
peptide FLPSDYFPSV (FLP) from the hepatitis B virus core
protein were obtained from the NIH Tetramer Core Facility
(hereafter these molecules are referred to as Mamu-A1/Gag,
Mamu-A1/Tat, and Mamu-A1/FLP). Tetramers were made by
mixing 6 aliquots of FITC-labeled ExtraAvidin (Sigma) with MHC
monomers over the course of 8 hours to a final molar ratio of
1:4.5. For tissue sectioning, fresh tissues were embedded in low
melt agarose and cut into 200 micron thick sections. For the
primary incubation, tissues where incubated with MHC tetramers
at a concentration of 0.5 ug/ml in 1 ml of cold phosphate buffered
saline containing 100 mg/ml heparin (PBS-H) with 2% normal
goat serum at 4uC overnight. Sections were then washed with
chilled PBS-H, fixed with 4% paraformaldehyde for 2 hours at
room temperature, and again washed with PBS-H. For antibody
counterstaining, prior to secondary incubation, tissues were boiled
three times in 0.01 M Urea to expose epitopes, then permeabilized
and blocked with PBS-H containing 0.3% triton X-100 and 2%
normal goat serum for 1 hour. For the secondary incubation,
sections were incubated with rabbit anti-FITC antibodies (BioDe-
sign) diluted 1:10,000 in blocking solution at 4uC on a rocking
platform overnight. For the tertiary incubation, sections were
washed with PBS-H and incubated with Cy3-conjugated goat anti-
rabbit antibodies (Jackson ImmunoResearch) diluted 1:5000 in
blocking solution for 1 to 3 days, then washed again, post-fixed
with 4% paraformaldehyde for 1 h, and mounted on slides with
warmed glycerol gelatin (Sigma) containing 4 mg/ml n-propyl
gallate. Sections were counterstained with several combinations of
antibodies during primary, secondary, or tertiary incubations
including: primary rat-anti-human CD8 antibodies diluted 1:200
(AbD Serotec clone YTC182.20) or rat-anti-human CD3
antibodies diluted 1:200 (AbD Serotec clone CD3-12) followed
by tertiary Cy5-conjugated anti-rat antibodies (Jackson Immu-
noResearch) diluted 1:2000, and secondary mouse anti-CD20
antibodies diluted 1:200 (Novacastra clone L26) or mouse anti-
human Ki67 diluted 1:200 (Vector clone MM1) followed by
tertiary Alexa 488-conjugated goat anti-mouse antibodies (Molec-
ular Probes) diluted 1:2000 and goat anti-human IgM-Dylight 649
(1:2000) (Jackson ImmunoResearch).
Imaging
Confocal images were collected using a FluoView 1000 confocal
microscope with a 206 objective and 3 mm z-steps. Confocal z-
series were collected from approximately 5 mm from surface of the
tissue section to as deep as the antibody counter-staining
penetrated, approximately 35 mm into the tissue. Three-dimen-
sional montage images of multiple 8006800 pixel 200X Z-scans
were created using Olympus FluoView Viewer software.
Quantification of cells
To determine the density of SIV-specific CD8 T cells in tissues,
cells stained with Mamu-A1/Gag, Mamu-A1/Tat, and negative
control Mamu-A1/FLP tetramers were counted in single z-scan
montages of lymphoid and genital tissues. We stepped up and
down through the z-scans to distinguish tops and bottoms of cells
from non-specific background staining. Olympus FluoView
Viewer software was used to delineate tissue areas and count
tetramer+ cells in delineated areas. Image J software was then used
to measure the areas delineated for cell counts. Because tetramer+
cells were most highly concentrated within the lamina propria of
genital tissues, and because amounts of epithelium, lamina propria
and underlying muscularis varied between samples and sections, in
genital tissues we focused our quantification on tetramer+ cells in
the lamina propria. Multiple confocal fields were evaluated for
each sample covering 0.7 to 19 mm2, and averaging 3.1 mm2 in
lymphoid tissue samples, and covering 0.23 to 14 mm2, averaging
2.2 mm2 in genital lamina propria samples. Data are presented as
the total numbers of tetramer+ cells counted divided by the total
area measured for each tissue from each animal. For the
determination of the percentage of tetramer+ cells that were
Ki67+, we quantified all of the whole tetramer+ cells present in
each z-series montage image. We tested for differences between
independent groups using a 2 sample t-test with common variance.
SIVmac251 quantification
A real time qRT-PCR assay employing primers that specifically
amplify WT-SIVmac251, even in the presence of SIVDnef
sequences, was used to quantify SIVmac251in plasma essentially
as described [30].
Association of viral load and SIV-specific CD8 T cell
concentrations
To test for an association between plasma viral load and Mamu-
A1/Gag and Mamu-A1/Tat-binding cell concentration simulta-
neously, a multivariate linear model was fit to the logarithms of all
of the variables with the 2-vector of Mamu-A1/Gag and Mamu-
A1/Tat values as the response variable and viral load as the
predictor variable. These models allowed for correlation from
Mamu-A1/Gag and Mamu-A1/Tat-binding cell levels within the
same individual. Parameters were estimated using maximum
likelihood and standard errors were obtained by numerically
inverting the observed Fisher information matrix and taking the
square root of the diagonal entries. Wald tests were used to test for
SIV-Specific CTL In Situ in Immunized Macaques
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associations between explanatory variables (Mamu-A1/Gag and
Mamu-A1/Tat-binding cell levels) and viral load. This analysis
was conducted separately for each tissue. Correlations were
estimated using Pearson’s correlation coefficient; however, the test
for an association was based on the Wald test from the
multivariate linear model. Such an approach uses the correlation
between Mamu-A1/Gag and Mamu-A1/Tat-binding cells to get a
test with improved power as it provides more precise estimates of
the parameters.
Results
Experimental Design
The ‘‘enough and soon enough’’ hypothesis predicts: 1) that
SIV-delta nef vaccination would elicit/establish a resident or rapid
responder population of CD8 T cells located at the right time and
place to contain infection following vaginal challenge at the portal
of entry, or after dissemination to LTs; and 2) that the resident or
responder populations will be distinguished by location, numbers
or functions that might correlate with the maturation of protection
between 5 and 20 weeks after SIVDnef vaccination. We examined
these predictions (see Figure 1 for a schematic overview) in 16
Mamu-A1*001:01 rhesus macaques vaccinated intravenously with
SIVDnef: after vaccination, but before protection is established,
analyzing samples obtained at 2 weeks (n = 1 animal) and 5 weeks
(n = 4 animals) after SIVDnef vaccination and after protection has
‘‘matured’’ at 20 weeks (n = 4 animals). We also analyzed samples
obtained in the first 2 weeks following high dose vaginal WT-SIV
challenge at 20 weeks post-SIVDnef vaccination (n= 7 animals),
using in situ tetramer staining (IST) and complementary
techniques to determine in genital and lymphoid tissues the
location, numbers, and other characteristics of the CD8 T cells
specific for immunodominant epitopes in Gag and Tat.
Location of SIV-specific CD8 T cells in situ
We determined the location of immunodominant SIV epitope
Gag- and Tat-specific CD8 T cells in cervix, vagina, draining
lymph nodes, peripheral lymph nodes, spleen and ileum tissues,
using in situ MHC-tetramer staining [28,29] with Mamu-A1/Gag
and Mamu-A1/Tat tetramers. As a negative control, tissues were
stained with Mamu-A1 tetramers loaded with an irrelevant
peptide (Mamu-A1/FLP). T cells and B cells were also visualized
in the tissue sections by immunohistochemisty using antibodies
directed against CD8, CD3, and CD20. We detected
CD8+CD3+CD202Mamu-A1/Gag and Mamu-A1/Tat tetramer+
T cells distributed amongst other CD8 T cells in the lymphoid and
genital tissues from animals evaluated both before and after the
predicted maturation of protection, and after challenge with WT-
SIV.
At the portal of viral entry in cervical and vaginal tissues,
tetramer+ cells were predominantly located within the lamina
propria (Figure 2), but tetramer+ cells were also detected in the
epithelial layer in approximately half of the animals at each time
point. When detected in the genital epithelium, tetramer+ cells
were in lower abundance relative to the lamina propria (3–25 fold
less), and tended to be most concentrated near the border of the
epithelium and lamina propria. The predominant localization of
SIV-specific-tetramer+ cells in the lamina propria of genital tissues
is similar to what we found in genital tissues from non-vaccinated
WT-SIV infected rhesus macaques [31] and SHIV 89.6 vacci-
nated rhesus macaques (P.J. Skinner unpublished results), and this
localization is consistent with the previously described localization
of CD8 T cells in genital tissues from rhesus macaques [32] and
women [33] indicating that the localization of SIV-specific CD8 T
cells identified here is not specific for SIVDnef vaccination.
In proximal, mid, and distal vagina tissues at 2 weeks post-
vaccination, many T and B cells including tetramer+ cells
surrounded vessels (Figure 3), some of which were clearly arterial.
In addition, at all time points, tetramer+ cells were located within
lymphoid aggregates in the cervix and vagina. These lymphoid
aggregates, comprised of predominantly CD8 T cells (Figure 2,
and Figure 4), were located throughout the lamina propria from
just beneath the epithelium to near the muscularis (Figure 2), as
well as within the muscularis, and ranged in size from ,60 mm to
over 500 mm in diameter. There were no obvious distinctions in
the location of tetramer+ cells in genital tissues over the time
course for development and maturation of LAV-SIVDnef induced
protection, between 5 and 20 weeks post-vaccination, or after
challenge with WT-SIV. In lymph nodes, tetramer+ cells were
primarily located in T cell zones (Figure 5A), whereas in spleen,
tetramer+ cells were most abundant in the red pulp, with fewer
cells located in the T cell zone and B cell follicles in the marginal
zones (Figure 5B). In tissue sections of ileum, tetramer+ cells were
located throughout the lamina propria and Peyer’s patches (Figure
S1). Within all of the lymphoid tissues, tetramer+ cells were often,
but not always, in relatively lower abundance or largely absent
Figure 1. Study overview. Mamu-A1*001:01 rhesus macaques were vaccinated intravenously with SIVmac239Dnef and intravaginally challenged
20 weeks later with WT-SIV. Individual animal numbers are indicated at the day post-SIVDnef vaccination (dpv, upper row) or day post-challenge with
WT-SIV (dpc, lower row) that animals were evaluated.
doi:10.1371/journal.pone.0081623.g001
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from B cell follicles (Figure 5B). When there were tetramer+ cells in
the follicles, they were often most abundant at the edge adjoining
the T cell zone. No observed change in location of tetramer+ cells
was observed within lymphoid tissues, between 5 and 20 weeks
post-vaccination, or after challenge with WT-SIV.
Abundance, activation and proliferative state of SIV-
specific CD8 T cells in situ
We determined the population densities and activation and
proliferative state of tetramer+ SIV-specific CD8 T cells in situ in
the lamina propria of cervix and vagina, as well as in draining
lymph nodes, peripheral lymph nodes, and spleen, by IST
staining, and staining for Ki67 as a marker for activation and
proliferation (Figures 6 and 7). Tat-tetramer+ cells were less
Figure 2. Localization of SIV-specific CD8+ T cells in cervix and vagina. A) Top panels show representative images of endocervix from an
animal (137.09) at 5 weeks post-SIV-Dnef vaccination as examples of the low end of the spectrum of levels of tetramer+ detected in genital tissues
amongst the whole cohort. Mamu-A1/Gag tetramer+ cells are red to pink, CD8+ T cells are blue, and CD20+ cells are green. B) In the bottom panels
Mamu-A1/Tat MHC-tetramer-binding cells are red to pink, CD3+ T cells are blue, and CD20+ B cells are green from a representative image of vagina
from animal#338.02, 21 weeks post-SIV-Dnef vaccination and 7 days following vaginal challenge with WT-SIV, as an example of the higher end of the
spectrum of levels of tetramer+ cells detected in genital tissues amongst the whole cohort. The edge of the epithelium (E) is indicated with a white
line; lamina propria indicated by LP. For both A) and B), the left panel shows a montage of several confocal projected z-series images (projected z-
series are images collected a different depths stacked on top of each other), collected with a 206objective. The right panels shows enlargements
with several red to pink tetramer+ cells evident (indicated by arrows in A) localized diffusely as well as within small T cell aggregates. Scale
bars = 100 mm.
doi:10.1371/journal.pone.0081623.g002
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Figure 3. Localization of SIV-specific CD8 T cells in vagina at 14 days post-vaccination. Representative confocal image showing Mamu-
A1/Gag tetramer+ cells (red), CD8 (blue), and CD20 (green). The right panel shows a montage of projected z-series of several 2006 fields with the
epithelium (E), lamina propria (LP), muscularis (M), and areas with vessels (V) indicated. In the enlarged image on the left, tetramer+ cells are indicated
with arrows. Scale bars are 100 mm.
doi:10.1371/journal.pone.0081623.g003
Figure 4. Most CD3+ T cells were CD8+ in genital lymphoid aggregates. Representative images of endocervix section stained with Mamu-A1/
Gag tetramers (red), CD8 antibodies (green), and CD3 antibodies (blue) from animal #338.02. Tetramer+ cells are indicated with white arrows in the
enlargement. The bottom panels show individual tetramer and antibody stains. Note most CD3+ T cells are CD8+. The top left panel shows a montage
of projected z-series of several 2006 fields. Scale bars = 100 mm.
doi:10.1371/journal.pone.0081623.g004
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Figure 5. Localization of SIV-specific CD8+ T cells in lymph nodes and spleen. The representative images shown in are A) from an axillary
lymph node from an animal (119.96) 5 weeks post-SIV-Dnef vaccination. Mamu-A1/Tat tetramer+ cells are red to pink, CD8+ T cells are green, and
CD3+ T cells are blue. The left panel shows a montage of several fields containing projected z-scans collected with a confocal microscope 206
objective. Enlargements to the right show individual fields of projected z-scans collected with a 606objective. The representative images shown in B)
are from a spleen section from an animal (119.96) at 5 weeks post-SIVDnef vaccination. Mamu-A1/Gag tetramer+ cells are red to pink colored, CD8+ T
cells are blue, and CD20+ B cells are green. Tetramer+CD8+ cells localized with other CD8 T cells and were most abundant in the red pulp (RP) and
marginal zones (MZ), with relatively fewer located in T cell zones (T) and in B cell follicles (B). The left panel shows a montage of several confocal
microscope fields of projected Z-scans stitched together, collected with a 106 objective. Enlargements show individual confocal z-scans of single
2006 fields.
doi:10.1371/journal.pone.0081623.g005
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frequent in lymphoid tissues (Figure 6A), but not in cervical
vaginal tissues (Figure 6C), at 20 weeks post-vaccination compared
to 5 weeks post-vaccination, consistent with initial expansion and
then contraction of the immune response associated with the
declining SIVDnef replication described elsewhere, as well as the
evolution of escape in the Tat SL8 epitope (R. K. Reeves et al., ms.
in preparation). Expression of the cell activation and proliferation
marker Ki67 in SIV-specific CD8 T cells in situ at these sites was
also consistent with this interpretation for both in LTs and cervical
vaginal tissues (Figure 7). However, remarkably high percentages,
averaging 38%, and ranging as high as nearly 80%, of tetramer+
cells were Ki67+ in the genital tissues (Figure 7C, D). SIVDnef
RNA was detected within lymphoid tissues of all animals at all
time points (A.T. Haase and J.D. Lifson et al., manuscript in
preparation), supporting the idea that ongoing SIVDnef replica-
tion could be sustaining activation and ongoing proliferation of
SIV-specific CD8 T cells in LTs and genital tissues. While the
abundance of Mamu-A1/Tat-specific tetramer+ cells did not
increase significantly following vaginal challenge, either in LTs or
cervical vaginal tissues, there was a marginally significant increase
in Mamu-A1/Tat-tetramer+ Ki67+ cells following challenge in
cervical vaginal tissues, consistent with a recall response
(Figure 7C).
The numbers of Mamu-A1/Gag-tetramer+ cells did not
contract significantly between 5 and 20 weeks post-SIVDnef
vaccination (Figure 6B, D), but, in LTs, the frequency of Mamu-
A1/Gag-tetramer+Ki67+ cells did decrease significantly
(Figure 7B). However, there was no evidence for a recall response
of Mamu-A1/Gag-tetramer+ cells from changes in abundance
(Figure 6B, D) or increases in Ki67+ cells (Figure 7B, D) following
vaginal challenge.
Association of viral load and SIV-specific CD8 T cell levels
in lymph nodes
We compared levels of WT-SIV RNA in plasma (Table 1) to the
tissue densities of Mamu-A1/Gag- and Mamu-A1/Tat-tetramer+
T cells detected in tissues to determine if there were correlations
between the quantities of virus-specific CD8 T cells and plasma
WT-SIV virus load in the three animals (56.05, 434.01, and
389.02) in which WT-SIV was detectable. We found a significant
Figure 6. Abundance of SIV-specific CD8 T cells in lymphoid and genital tissues. The number of MHC-tetramer+ cells per mm2 in lymphoid
tissues is presented in panels A) and B) and in the lamina propria of genital tissues in panels C) and D). The tissue density of Mamu-A1/Tat stained
cells are shown in A) and C), and Mamu-A1/Gag stained cells shown in B) and D). Animal numbers, days post-SIVDnef vaccination (dpv) and days post-
challenge (dpc) are indicated below each graph. Negative control sections stained with Mamu-A1/FLP showed a range of 0-3.4 cells/mm2 and
average of 1.25 cells/mm2 in lymphoid tissues, and 0 cells/mm2 in the genital tissues.
doi:10.1371/journal.pone.0081623.g006
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positive association between Mamu-A1/Gag binding cells within
the lymph nodes and plasma viral loads (genital p = 0.025,
mesenteric p = 0.00032, and axillary p= 0.017) (Figure 8); and
levels of Mamu-A1/Gag and Mamu-A1/Tat binding cells within
individual animals were highly associated (p= 0.0072).
Discussion
In this study, we determined by IST staining, the number and
location of tetramer+ SIV-specific CD8 T cells at the critical early
times and sites in the genital and lymphoid tissues where
respectively infection begins and to which it is disseminated in
unvaccinated animals. We were particularly interested to deter-
mine if SIVDnef vaccination would convert the previously
described ‘‘too little, too late’’ CD8 T cell response observed in
unvaccinated animals [22,23] to an ‘‘enough and soon enough’’
response in which virus-specific CD8 T cells would constitute a
resident or rapid responder population at the portal of entry to
control infection there, or contain infection after virus spread to
the lymphoid tissues. The detection reported here of Mamu-A1/
Gag and Mamu-A1/Tat tetramer+ CD8 T cells distributed
amongst other CD8 T cells in lymphoid and genital tissues at all
time points examined, including the time of vaginal challenge,
stands in stark contrast to our previous observation in unvacci-
nated vaginally inoculated animals in which SIV-specific CD8 T
cells were not detectable in genital or lymphoid tissues until the
second week following vaginal inoculation [22], and is consistent
with the concept of a resident population of cells operating at an
advantage against the small populations of infected cells in the
early stages of infection. Our findings are consistent too with our
previous studies in animals vaccinated with an attenuated SHIV
and vaginally challenged with SIV in which with a resident
population of virus-specific CD8 T cells in genital and lymphoid
tissues was associated with protection [34].
Figure 7. The percentage of tetramer+ SIV-specific CD8 T cells that were expressing the proliferation marker Ki67. The percentage of
Mamu-A1/Tat tetramer+ cells (A and C) and Mamu-A1/Gag tetramer+ cells (B and D) that were Ki67+ in genital lymph nodes, axillary lymph nodes,
mesenteric lymph nodes, and spleen is shown in the top panels and in vagina and cervix is shown in the bottom panels. Animal numbers, days post-
SIVDnef vaccination (dpv) and days post-challenge with WT-SIV (dpc) at necropsy are indicated below each graph. Significant decreases in the
percentage of tetramer stained cells that were Ki67+ was observed in animals at 5 weeks (,35 dpi) compared to 20 weeks (,140 dpi) post-SIVDnef
vaccination. A significant increase in the percentage of Mamu-A1/Tat tetramer+ cells was observed in genital tissues during the first two weeks after
challenge compared to animals just prior to challenge. *p-values are indicated. No significant difference was observed with Mamu-A1/Gag or Mamu-
A1/Tat tetramer+ cells just prior to challenge compared to the first two weeks after challenge in lymphoid tissues or with MamuA1/Gag staining in
genital tissues.
doi:10.1371/journal.pone.0081623.g007
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The numbers and locations of the tetramer+ cells, however,
cannot by themselves account for the maturation of protection
between 5 and 20 weeks post-vaccination, since the decrease
between 5 and 20 weeks in the numbers of tetramer+ cells, and
tetramer+Ki67+ cells is inversely related to the increasing
protection, and is most consistent with the contraction phase of
an immune response that parallels the declining levels of SIVDnef
replication in the tissues. Furthermore, the density of the virus-
specific CD8 T cell population patrolling the portal of entry in the
vaccinated animals is at least five-fold smaller than the density of
the populations achieved by three weeks following vaginal
inoculation in unvaccinated animals that was associated with 50
to 100-fold reductions in tissue VL from peak levels [24].
Virus-specific CD8 T cells, nonetheless, could be involved in the
maturation of protection between 5 and 20 weeks in two ways.
First, there could be a change in the ‘‘quality’’ of the CD8 T cells
as effectors that correlates at 20 weeks with phenotypic changes in
the virus-specific CD8 T cells. Second, there could be a change in
non-T cell immune components of the immune system such as the
maturation of a vaccine-induced antibody response at the portal of
viral entry that might help reduce the establishment and expansion
of founder populations of infected cells, thereby creating an
Figure 8. Comparison of plasma WT-SIV virus load and tissue densities of tetramer+ SIV-specific CD8 T cells. Tissue densities of Mamu-
A1/Gag (blue) and MamuA1/Tat (red) tetramer+ cells for each tissue including genital, mesenteric, and axillary lymph nodes, spleen, vagina and cervix
compared to levels of WT-SIV in plasma. Plasma viral load value listed as 10 were below the limits of detection of the assay. A significant positive
association was observed between the plasma viral load and MamuA1/Gag tetramer+ cells in lymph nodes.
doi:10.1371/journal.pone.0081623.g008
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environment in which virus-specific CD8 T cells would be
operating at numerically superior numbers compared to any
infected targets in the early stages of infection at 20 weeks but not
at 5 weeks. Paradoxically, in this hypothetical reconstruction of the
correlates of the maturation of protection, the marginally
significant increase in Tat tetramer+ cells at the portal of entry,
and positive associations between plasma VL and tetramer+ cells
in lymphoid tissues could actually represent a failure of first line
defenses to successfully fully contain infection. The role of the
virus-specific CD8 T cell then becomes the more conventional one
of partial control of systemic infection, with the increased levels of
tetramer+ cells reflecting cells responding to antigenic drive from
the breakthrough infection with the challenge virus. It will thus be
of interest in future studies to design vaccine strategies that would
be more effective than SIVDnef in inducing and maintaining a
larger population of effector CTLs that would work in concert
with the local humoral immune response to fully contain and
eliminate infected cells at the portal of entry.
Supporting Information
Figure S1 Localization of SIV-specific CD8 T cells in
ileal Peyer’s patches. The representative images shown are
from animal #174.96 stained with Mamu-A1/gag tetramers (red),
CD20 antibodies (green), and CD3 antibodies (blue). Tetramer+
cells were localized throughout the Peyer’s patches of ileum tissue
sections with other T cells around as well as within B cell follicles.
The left shows a montage of several confocal Z-scan fields stitched
together, collected with a 206 objective.
(TIF)
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